

HS10160/HS10241 synergism in breast and ovarian cancer




Figure S1. H₂O₂-induced PARylation is inhibited by olaparib. MDA-MB-231 cells were treated with olaparib at indicated concentration for overnight and subjected to 20 mM H₂O₂ treatment for 20 min. Cells were then harvested for Western blotting analysis for detecting PARylation (PAR) and PARP1 expression. Actin were used as protein quantity loading control among different samples.




Figure S2. H₂O₂-induced MET activation is inhibited by crizotinib. MDA-MB-231 cells were treated with crizotinib at indicated concentration for 3 h before subjected to 20 min, 20 mM H₂O₂ treatment. Cells were then harvested for Western blotting analysis for detecting p-Y1234/1235 MET (p-MET) and MET expression. Actin were used as protein quantity loading control among different samples.

HS10160/HS10241 synergism in breast and ovarian cancer




Figure S3. Cytotoxicity of HS-10160 in TNBC and HGSOc. Cells indicated were treated with different concentrations of HS10160 for 3 days before cell survival were measured by using MTT assays. Data from un-treated group were used as 100% survival to normalize survival rate in response to different HS-10160 concentrations. Mean \pm S.E.M. were plotted and interpolated curve is generated by using GraphPad Prism 8 with asymmetric sigmoidal curve.

HS10160/HS10241 synergism in breast and ovarian cancer




Figure S4. Cytotoxicity of HS-10241 in TNBC and HGSOC. Cells indicated were treated with different concentrations of HS10241 for 3 days before cell survival were measured by using MTT assays. Data from un-treated group were used as 100% survival to normalize survival rate in response to different HS-10160 concentrations. Mean \pm S.E.M. were plotted and interpolated curve is generated by using GraphPad Prism 8 with asymmetric sigmoidal curve.